Verrica Pharmaceuticals Inc (VRCA)
8.69
-0.01
(-0.11%)
USD |
NASDAQ |
May 21, 14:01
Verrica Pharmaceuticals Enterprise Value: 362.96M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 362.96M |
| May 17, 2024 | 361.69M |
| May 16, 2024 | 382.05M |
| May 15, 2024 | 379.93M |
| May 14, 2024 | 396.48M |
| May 13, 2024 | 399.45M |
| May 10, 2024 | 333.27M |
| May 09, 2024 | 326.48M |
| May 08, 2024 | 316.73M |
| May 07, 2024 | 318.42M |
| May 06, 2024 | 304.00M |
| May 03, 2024 | 301.88M |
| May 02, 2024 | 280.67M |
| May 01, 2024 | 284.49M |
| April 30, 2024 | 289.36M |
| April 29, 2024 | 297.21M |
| April 26, 2024 | 285.34M |
| April 25, 2024 | 276.00M |
| April 24, 2024 | 281.94M |
| April 23, 2024 | 284.49M |
| April 22, 2024 | 281.94M |
| April 19, 2024 | 290.00M |
| April 18, 2024 | 286.61M |
| April 17, 2024 | 293.39M |
| April 16, 2024 | 290.85M |
| Date | Value |
|---|---|
| April 15, 2024 | 287.46M |
| April 12, 2024 | 285.34M |
| April 11, 2024 | 293.82M |
| April 10, 2024 | 298.91M |
| April 09, 2024 | 292.97M |
| April 08, 2024 | 290.85M |
| April 05, 2024 | 279.40M |
| April 04, 2024 | 266.25M |
| April 03, 2024 | 255.22M |
| April 02, 2024 | 243.76M |
| April 01, 2024 | 245.04M |
| March 31, 2024 | 245.04M |
| March 28, 2024 | 224.45M |
| March 27, 2024 | 212.99M |
| March 26, 2024 | 198.99M |
| March 25, 2024 | 187.97M |
| March 22, 2024 | 185.84M |
| March 21, 2024 | 187.54M |
| March 20, 2024 | 183.72M |
| March 19, 2024 | 174.39M |
| March 18, 2024 | 174.82M |
| March 15, 2024 | 176.94M |
| March 14, 2024 | 181.18M |
| March 13, 2024 | 192.21M |
| March 12, 2024 | 193.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.43M
Minimum
Nov 09 2022
414.05M
Maximum
Mar 15 2021
214.08M
Average
208.28M
Median
Mar 18 2022
Enterprise Value Benchmarks
| Emergent BioSolutions Inc | 1.131B |
| Macrogenics Inc | 82.58M |
| Aquestive Therapeutics Inc | 223.99M |
| Recursion Pharmaceuticals Inc | 2.029B |
| Omega Therapeutics Inc | 94.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.33M |
| Revenue (Quarterly) | 3.826M |
| Total Expenses (Quarterly) | 22.42M |
| EPS Diluted (Quarterly) | -0.44 |
| Gross Profit Margin (Quarterly) | 70.26% |
| Profit Margin (Quarterly) | -531.4% |
| Earnings Yield | -20.25% |
| Normalized Earnings Yield | -19.62 |